Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial. - Seaton KE; Paez CA; Yu C; Karuna ST; Gamble T; Miner MD; Heptinstall J; Zhang L; Gao F; Yacovone M; Spiegel H; Dumond JB; et al. (The lancet. HIV, 2025)